1
/
of
0
FDA FAERS Report – Emend
FDA FAERS Report – Emend
Regular price
$69.00 USD
Regular price
Sale price
$69.00 USD
Unit price
/
per
Original Request: Request for MedWatch Report for Product Case ID 24252445, Suspect Product: Emend (Aprepitant;Tebentafusp), Reason for Use: Metastatic Ocular Melanoma;Nausea, Reaction: Brain Fog;Drug Intolerance;Product Use In Unapproved Indication;Loss Of Personal Independence In Daily Activities, Non-Serious, Sex: Female, Country: US, MCN: US-009507513-2408USA0072
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details